Background Current treatment recommendations for patients with polycythemia vera call for
maintaining a hematocrit of less than 45%, but this therapeutic strategy has not been tested …

Age older than 65 years, hemoglobin level lower than 100 g/L (10 g/dL), white blood cell
count greater than 25 × 10 9 /L, peripheral blood blasts 1% or higher, and constitutional …

Diagnosis of essential thrombocythemia (ET) has been updated in the last World Health
Organization (WHO) classification. We developed a prognostic model to predict survival at …

Ruxolitinib is a Janus kinase (JAK)(JAK1/JAK2) inhibitor that has demonstrated superiority
over placebo and best available therapy (BAT) in the Controlled Myelofibrosis Study with Oral …

The phenotype induced by the GATA-1 low (neoδHS) mutation is here further characterized
by analyzing the hemopoietic system during the aging (up to 20 months) of a GATA-1 low …

Here it is shown that the phenotype of adult mice lacking the first enhancer (DNA hypersensitive
site I) and the distal promoter of the GATA-1 gene (neoΔHS or GATA-1 low mutants) …

In an international study of 1104 patients with essential thrombocythemia (ET), a histological
review according to the 2008 World Health Organization (WHO) criteria confirmed ET in 891 …

Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) with a high propensity
to develop acute myeloid leukemia, named at this stage blast phase (BP) of PMF. 1 …

Background There is no evidence that phlebotomy alone is sufficient to steadily maintain
haematocrit on target level in low-risk patients with polycythaemia vera. This study aimed to …

Polycythaemia vera is associated with a reduced quality of life, a high rate of vascular events,
and an intrinsic risk of disease evolution. The results of several randomised trials for the …